HHS & Healthcare Contracts Intelligence — July 10, 2026

Leidos Biomedical Research won a full-and-open competition for a $87.1M delivery order from NIH NCI, signaling competitive strength in life sciences R&D services. The cost-plus-fixed-fee structure reduces profit volatility and provides stable margins.

Only $21.6M (25%) of the $87.1M total has been outlaid as of award date, with a current end date of August 2026. Most revenue is forward-looking and subject to performance risk and option exercise.

This is the only contract in the digest, representing 100% of the aggregate value. No diversification across agencies or contractors increases single-point-of-failure risk for this digest's analysis.

Leidos can leverage this NIH NCI win to pursue follow-on awards and scope modifications that could increase the total obligation beyond $87.1M, given the full-and-open competitive win.

The $87.1M award to Leidos under full-and-open competition reflects continued NIH investment in health R&D services, particularly for the NIAID VRC, which aligns with government priorities in biomedical research.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"The $87.1M NIH award represents a competitive win but has low initial outlay ($21.6M), making revenue recognition and option exercise key to near-term performance.", "trigger"=>"Option exercise by August 2026, quarterly earnings reports for revenue recognition"}